Related by context. All words. (Click for frequent words.) 63 Hill Rom enhancing 63 periodically reassessed 63 CINQUIL 63 via intradermal injections 62 infliximab monotherapy 62 CIMZIA TM certolizumab pegol 61 prospectively stratified 61 Raptiva r 61 receiving CIMZIA #mg 61 Tumor Response 60 registrational Phase 60 ADCS CGIC 60 stage IIIb IV 60 morphometric vertebral fractures 60 desvenlafaxine succinate 60 EDEMA3 trial 60 Mentalist Ulrich 60 treatment naive genotype 60 CIMZIA ™ 60 prednisone prednisolone plus 59 evaluating Actimmune 59 irinotecan cisplatin 59 BRIM2 59 null responder HCV 59 amalgam fillings mercury vapor 59 galiximab 59 J Antimicrob Chemother 59 Negative Symptoms 59 Montgomery Asberg Depression 59 placebo controlled dose escalation 58 ACTEMRA TM 58 undergoing elective percutaneous 58 Secondary endpoints include 58 blinded randomized placebo controlled 58 0 SHOTS OFF 58 8mg/kg 58 Inventory BPI 58 dose escalation phase 58 Zevalin consolidation 58 oral deforolimus 58 FOLFOX4 58 confirmed CCyR 58 CR nPR 58 PITX2 methylation 58 #:#-# Abstract Free [009] 58 Oral NKTR 58 evaluating tivozanib 58 CRp 58 weekly subcutaneous injections 58 Hamilton Anxiety Scale 58 d l leucovorin 58 maximal tolerated 58 plus prednisone 58 gp# vaccine 58 Impaired fasting glucose 58 Brief Psychiatric 58 MoxDuo TM IR 57 unresectable tumors 57 solid tumors ZYBRESTAT 57 tumor histology 57 severe hepatic dysfunction 57 Solid Tumors 57 achieved CCyR 57 phase IIb study 57 angiographic outcomes 57 CCyR 57 Bayer HealthCare Onyx Pharmaceuticals 57 asymptomatic metastatic 57 postoperative chemotherapy 57 Secondary efficacy endpoints 57 MAGE A3 ASCI 57 mg Pycnogenol 57 Zometa hazard 57 Erectile function 57 Nothing Wadden 57 haematologic 57 recurrent malignant glioma 57 Pechanga Theater 57 Harpo Studios produces 57 azilsartan medoxomil 57 preoperative intraoperative 57 Scale EDSS 57 nucleoside naive 57 Oral Fingolimod 57 Heterozygous Familial Hypercholesterolemia 57 Cystic Fibrosis Questionnaire Revised 57 oxycodone CR 57 Index CDAI 57 pegylated interferon alpha 57 Randomized Phase II 57 pertuzumab 57 malignant mesothelioma Alfacell 57 Nesiritide 57 Depressed bipolar 57 achieved sustained virologic 57 Folfox 57 endothelin antagonists 57 Montgomery Åsberg Depression 57 antiretroviral naïve 57 PREZISTA r arm 57 rALLy clinical trial 57 pegylated interferon alfa 2b 57 interferon gamma 1b 57 ARTHRITIS AQUATIC PROGRAM 56 Quinamed 56 prospectively defined 56 HIV HCV coinfected 56 RECIST Response Evaluation Criteria 56 NATRECOR R 56 refractory chronic lymphocytic 56 Scale PANSS 56 visit www.BYETTA.com 56 statistically significant efficacy 56 5 Fluorouracil 56 See CLINICAL PHARMACOLOGY 56 secondary efficacy endpoint 56 HIV RDEA# 56 ZOLINZA 56 SuperMedia specializes 56 EMBLEM TM 56 Receives URAC 56 recurrent glioblastoma multiforme 56 MGd 56 Jack Pirozzolo 56 Hormone Refractory Prostate Cancer 56 neuropathy sensory 56 CIPN 56 nab paclitaxel 56 Complicated Skin 56 serum phosphorous 56 Relapsed Refractory 56 Global Impression CGI 56 ATACAND 56 Coronary angiography 56 relapsing multiple sclerosis 56 rituximab refractory 56 REVIVE Diabetes 56 EMPOWER TM 56 Prospective Randomized 56 MET amplification 56 dose escalation clinical 56 metastatic HRPC 56 oral rivaroxaban 56 Group ECOG 56 active comparator 56 Rate ORR 56 RECIST criteria 56 ABSORB clinical 56 By LEON HALE 56 ug dose 56 doi Abstract Free 56 CARE HF 56 Ketotransdel TM 56 Primary endpoints 56 undergoing Percutaneous Coronary 56 HCV SPRINT 56 R# #mg BID 56 venlafaxine XR 56 EchoCRT 56 Relapsing Multiple Sclerosis 56 Cutaneous T 56 completely resected 56 CTAP# Capsules 56 Dr. Ihor Gussak 56 NCQA accreditation surveys 56 meta regression 56 riociguat 55 cerebral somatic oximeter 55 Group RTOG 55 non menstrual pelvic 55 Pharmacokinetic parameters 55 Search dailypress.com Web 55 DAS# CRP 55 achieved sustained virological 55 Negative Syndrome 55 KRAS status 55 By BOB SHERRILL 55 FirstLook pre feature 55 PANSS 55 MoxDuo IR 55 Aflibercept 55 SSRI SNRI 55 HORIZONS AMI trial 55 ord = + krdDartOrd 55 decompensated liver disease 55 damp squib sponge 55 NLX P# 55 peg interferon 55 Response Evaluation Criteria 55 certolizumab 55 BRIM3 55 Irvine Ladera Ranch 55 TMC# C# 55 SIMPADICO 55 bortezomib refractory 55 CIMZIA TM 55 achieved ACR# 55 4mg/kg 55 coinfected patients 55 Adjuvant chemotherapy 55 HORIZONS AMI 55 Secondary endpoints 55 #:#-#,# [002] 55 intravenous methylnaltrexone 55 products utilizing CPEX 55 assessing T DM1 55 HIV tropism 55 Neuropsychiatric Inventory NPI 55 plus OBT 55 relapsed MM 55 previously untreated follicular 55 Actress Merrin Dungey 55 Dr. Taublieb provides 55 K ras mutations 55 humanized interleukin 6 55 REMINYL ® 55 0 Thumbs Up 55 eTag assays 55 sustained virological response 55 FOLPI 55 Allovectin 7 ® 55 Secondary endpoints included 55 CALGB # [002] 55 myelodysplastic myeloproliferative diseases 55 INVEGA ® 55 HF ACTION 55 Flu Cy 55 TTF Therapy 55 chemoradiation therapy 55 CYP#D# genotype 55 insulin detemir 55 landmark ATHENA 55 EOquin TM phase 55 phase IIIb 55 IOP lowering 55 Alzheimer Disease Assessment 55 YMRS 55 tapentadol ER 55 low dose cytarabine 55 pharmacodynamic effects 55 HAQ DI 55 moderate renal impairment 55 Clinical Antipsychotic Trials 55 overnight polysomnography 55 multicenter multinational 55 sorafenib tablets 55 underwent resection 55 gadobutrol 55 erlotinib Tarceva ® 55 OnDose TM 55 erection hardness 55 pharmacogenetic tests 55 treatment naïve genotype 55 Abiraterone Acetate 55 cardiac perfusion imaging 55 eosinophilic asthma 55 Hotwire Reveals Hotel 55 chemotherapy molecularly targeted 55 mucosal healing 55 Irony lurks 55 BOXED WARNING 55 titrated glipizide 55 BENICAR HCT 55 LymphoStat B belimumab 55 aplindore 55 #:#-#,# CrossRef Medline [002] 55 AHIP Statement 55 oral ridaforolimus 55 recurrent glioma 54 REYATAZ r arm 54 retorted Behar 54 ASCEND HF 54 Connective Healthcare 54 EXJADE 54 IFN alfa 54 CLARITY study 54 symptomatic hyponatremia 54 Health Assessment Questionnaire 54 tipranavir ritonavir 54 Severity MSCS score 54 Ingenix OptumHealth 54 cisplatin gemcitabine 54 Motesanib 54 Randomized Double Blind 54 Intravenous iron 54 vaginal progesterone gel 54 HGS ETR2 54 Power3 Alzheimer disease 54 CNS LS 54 GAMMAGARD 54 plus glimepiride 54 imatinib therapy 54 Val HeFT 54 metastatic pancreatic 54 hourlong Pushing Daisies 54 Sensitivity specificity 54 Mg Uk 54 gemcitabine carboplatin 54 Hepatitis C Antiviral 54 CCX# B 54 TomoMobile ™ relocatable radiation 54 baseline HbA1c 54 Rating Scale MADRS 54 neuropsychological assessment 54 lopinavir r arm 54 everolimus eluting stents 54 INSPIRE Trial Phase III 54 TO AVOID PREGNANCY WHILE 54 Valvular Heart Disease 54 AVI antiviral programs 54 garnered Lindsay Abaire 54 fluoxetine paroxetine 54 hA# 54 alfa 2a 54 TWYNSTA 54 baseline PASI 54 J Shoulder Elbow 54 Arch Pediatr Adolesc Med 54 APPRAISE 54 Inc. IAAI wholly 54 nicardipine 54 limiting generalizability 54 oral FTY# 54 KAPVAY 54 pegylated interferon alpha 2a 54 placebo dexamethasone 54 Phase 1a clinical 54 tenofovir emtricitabine 54 plus dexamethasone 54 LUMINATE 54 PREZISTA r 54 therapist Psychologist 54 IMiDs ® compound 54 By JEFF SCHOGOL 54 Borrego Solar photovoltaic 54 randomizing patients 54 MEDai Pinpoint Review www.medai.com 54 HUMIRA achieved PASI 54 Alaskan Prospectors Society 54 dose proportionality 54 Non inferiority 54 ARB telmisartan 54 #.#mg/dL 54 Treatment Naive Patients 54 hemoglobin A1c HbA1c 54 Demonstrate Significant 54 radiographic outcomes 54 placebo controlled clinical 54 multicenter prospective 54 methotrexate monotherapy 54 SHOWS TO WATCH 54 underwent surgical resection 54 ANN INTERN MED 54 adenotonsillectomy 54 preoperative chemotherapy 54 forodesine 54 plus prednisone prednisolone 54 comparator arm 54 ACCORD Lipid 54 Search Courant.com Web 54 administer intraoperative radiation 54 Prosecutor Todd Keagle 54 Naive Patients 54 euthymic patients 54 ER CHOP 54 chemotherapy hormonal therapy 54 Edge STudy 54 Crohn Disease Activity 54 ADE# ineffective 53 croon Honky Tonk Woman 53 Heart Transplant Recipients 53 HCV RESPOND 2 53 annualized relapse 53 baseline A1C 53 blinded randomized controlled 53 intraobserver 53 mapatumumab 53 aplastic anemia AA 53 DEXA scan 53 PARTNER Trial 53 postintervention 53 antiangiogenic therapy 53 Sleep Disturbances 53 prespecified secondary 53 BEXXAR Therapeutic Regimen 53 GI motility disorders 53 iniparib BSI 53 attain statistical significance 53 nonrandomized 53 KRAS mutation status 53 standard chemotherapy regimen 53 cytogenetic response 53 Castration Resistant Prostate Cancer 53 randomized discontinuation 53 Fibromyalgia Impact Questionnaire 53 demonstrated antitumor activity 53 subsidiary PharmaCare 53 BENICAR 53 STRIDE PD 53 multicenter randomized controlled 53 Home Buyer Seller 53 oncology radiation oncology 53 Pooled Analysis 53 daily Infergen 53 Traficet EN 53 Dialysis Outcomes 53 therapy CBT 53 relapsed refractory multiple myeloma 53 -#.# log# copies mL 53 Ann Fam Med 53 CYP#A# substrate 53 Doxil ® 53 MCyR 53 linaclotide treated 53 EGFR mutation status 53 0 document.write 53 cognitive behavioral therapies 53 VBLOC vagal blocking 53 Myocardial Infarction Study 53 Randomized Phase 53 plus methotrexate 53 somatostatin analog 53 weekly CSBMs 53 CTA# Injection 53 unfractionated heparin UFH 53 KRAS mutations occur 53 drotrecogin alfa activated 53 ORENCIA ® 53 TeenNick Degrassi 53 glycosylated hemoglobin levels 53 prospective multicentre 53 adjunctive placebo 53 #:#-#,# CrossRef 53 co receptor tropism 53 Randomized controlled 53 Cancer Incidence Mortality 53 CHAMPION PCI 53 adjuvant chemotherapy 53 placebo fluoxetine 53 Mycophenolate Mofetil 53 sUA 53 Currency Majors Technical 53 hemoglobin A1c levels 53 administered cetrorelix 53 convergent validity 53 chemoembolization 53 viral kinetics 53 MEDai Pinpoint Review 53 DeWyze raspy tone 53 Index CDAI score 53 VBLOC TM 53 Inhaled Nitric Oxide 53 IES Consulting 53 dexamethasone Decadron 53 CORE OM 53 Free Survival PFS 53 psoriatic arthritis PsA 53 Search themorningcall.com Web 53 DO NOT THINK HE 53 evaluating REVLIMID 53 #mg/day [001] 53 device visit www.CalmareTT.com 53 Initiated Phase 53 Phase III VISTA 53 Group NCIC CTG 53 mcg BID 53 WHAT WOULD YOU SAY 53 Targretin capsules 53 EBMT criteria 53 MBHO 53 ExTRACT TIMI 53 Sham acupuncture 53 ADAS Cog 53 Symptom severity 53 Visual Analog Scale 53 MTP inhibitors 53 Warfarin Coumadin 53 tapentadol IR 53 asthma immunotherapeutic 53 teriflunomide 53 NIHSS score 53 neoadjuvant chemotherapy 53 Max Neeman 53 AVOREN 53 irbesartan 53 BFPET 53 clinico pathological 53 HBeAg seroconversion 53 Alzheimer Disease Cooperative 53 ancrod 53 relapsing remitting MS RRMS 53 Lindsay Abaire Rabbit Hole 53 protease inhibitor PI 53 hospitals physicians homecare 53 Treatment Outcome 53 clinically meaningful improvement 53 Decompensated Heart Failure 53 ascending dose 53 equi analgesic doses 53 adefovir treated 53 ICAEL 53 systemic immunosuppressive drugs 53 platelet reactivity 53 statistically significant superiority 53 HER2 positive metastatic breast 53 NCCTG N# 53 mg BID dose 53 Computerized tomography 53 PegIFN RBV 53 Opioid Use 53 paclitaxel cisplatin 53 BY CHRISTOPHER BEHNAN 53 BrachySil TM 53 differentiate squamous 53 thrombosis embolism 53 Cell Non Hodgkin 53 TomoMobile TM relocatable radiation 53 mutated K ras 53 Assigns Issuer Credit 53 + Hanzo 53 oral antidiabetes drugs 53 chemotherapy docetaxel 53 papillary renal cell carcinoma 52 LAB CGRP 52 abacavir lamivudine 52 ROCKET AF 52 follicular lymphomas 52 Physical Function 52 oral diclofenac 52 velafermin 52 thorough QTc 52 Gamunex C 52 STEP BD 52 RhuDex ™ 52 intravascular hemolysis 52 advanced hepatocellular carcinoma 52 HCAHPS survey 52 metastatic GIST 52 melphalan prednisone 52 TreeHouse Reseller View 52 Obes Res 52 Adjudicare software solution 52 Ann Oncol 52 neoadjuvant 52 schizophrenia schizoaffective disorder 52 remarkable #,#:# contrast 52 Mort Kondracke Executive 52 Score TOS 52 RECORD1 52 APTIVUS R 52 pharmacokinetic equivalence 52 DAS# scores 52 multi rater feedback 52 precaution Wiehle 52 HER2 expression 52 NAMCS 52 FOLFOX 52 Hedgehog inhibitor 52 rosuvastatin #mg 52 Carotid Revascularization Endarterectomy vs. 52 physiological nutritional 52 FOLFIRI 52 DSM IV diagnoses 52 NCCTG 52 refractory NSCLC 52 Multicenter Automatic Defibrillator Implantation 52 Vimpat R 52 Teen Mild Suggestive 52 DEB# 52 PegIFN 52 PEGylated interferon beta 1a 52 Genasense ® 52 NIHSS 52 echocardiographic parameters 52 MTWA testing 52 Understanding Universal BCAR 52 Dorel Marcu 52 Sustained virologic response 52 Visual Analogue Scale VAS 52 Arterial stiffness 52 visilizumab 52 Ocrelizumab 52 mso tstyle rowband size 52 gastroenterologists endocrinologists 52 complete cytogenetic response 52 CapMed Patient Portal 52 Index FSFI 52 Clinician Administered PTSD 52 Profile CAPP 52 Edinburgh Postnatal Depression 52 PRECiSE 52 Thrombolysis 52 AIR2 Trial 52 Thal Dex 52 prospective nonrandomized 52 aldosterone antagonist 52 virologic responses 52 Elevated triglycerides 52 By Dominic Casciani 52 vidofludimus 52 PatientKeeper Charge Capture 52 oxymorphone ER 52 crizotinib PF # 52 Warner Chilcott Actonel 52 peers Durning 52 permanently discontinue Vectibix 52 tocilizumab 52 capacities Garwood 52 VITAL Trial 52 radiolabeled TM# 52 cisplatin vinorelbine 52 WOMAC pain 52 EQ 5D 52 refractory indolent non 52 Ann Rheum Dis 52 Study Evaluating 52 Enzastaurin 52 + PH# 52 canakinumab 52 registrational trial 52 Pegasys peginterferon alfa 2a 52 XELOX 52 zoledronic acid Reclast 52 Neuropsychological Status 52 spontaneous bowel movements 52 patriotism Gration 52 Y BOCS 52 AGILECT R 52 PCWP 52 Bone Metastases 52 Turkey TUSKON 52 darunavir ritonavir 52 biliary tract cancer 52 RE LY 52 Angiographic 52 Mu Dynamics proactively 52 affective psychosis 52 #:#-#,# Medline 52 http:/events.fai.org 52 catheter ablations 52 randomized Phase IIb 52 COMBIVIR 52 HRQOL 52 candesartan cilexetil 52 AA Amyloidosis 52 CYPHER Stent 52 Gynecologic Oncology Group 52 Virologic 52 IFL chemotherapy regimen 52 farletuzumab 52 TAXUS VI 52 Newly Diagnosed Patients 52 comorbid disorders 52 Randomised 52 mg kg Hematide 52 Octreolin 52 Skin sterol 52 Advanced Renal Cell 52 ACRIN 52 Cheap generic levitra 52 symptom severity 52 paclitaxel poliglumex 52 metastatic neuroendocrine tumors 52 adjunctive ABILIFY 52 Cardiotoxicity 52 evaluating carfilzomib 52 UPDRS motor 52 Tekamlo 52 adverse cytogenetics 52 Psychiatry Clin Neurosci 52 demonstrated clinically meaningful 52 icatibant 52 Matt Lauer debriefed 52 ARIXTRA R 52 Annualized ROE 52 Pegasys ® 52 Engerix B 52 HERmark 52 sirolimus eluting stents 52 doxorubicin cyclophosphamide 52 Radiation Therapy Oncology 52 ADAS cog 52 PREZISTA ritonavir 52 adjuvant trastuzumab 52 LEXIVA r 52 clinicopathological features 52 nonpharmacologic 52 paclitaxel eluting stents 52 advanced metastatic renal 52 LHRH receptor positive 52 NSABP B 52 trials RCTs 52 QOPI 52 FDG-PET/CT 52 Inc. NASDAQ OMCL 52 Outpatient Setting 52 ejaculatory function 52 viral kinetic 52 Psoriasis Area 52 CPAP adherence 52 please visit www.medlinkus.com 52 Dual eligibles 52 % Confidence Interval 52 clinically meaningful reductions 52 indicates cardio circulatory 52 unified finite element 52 â ‰ ¥ 52 AVID elective 52 Demonstrated Significant 52 Peginterferon Alfa 2a 52 stage IIIb 52 By LYNNE ROSSETTO 52 guideline concordant 52 elotuzumab 52 ADCS ADL 52 sustained virologic response 52 ritonavir boosted 52 Global Impression 51 LUX Lung 51 Club Stairways Comprehensive 51 HBeAg negative patients 51 abdominal pain abdominal discomfort 51 ISTODAX ® 51 0 document.write sline 51 Caroline Klebl 51 achieved statistical significance 51 hormone deprivation 51 linear pharmacokinetics 51 HEARING LOSS OUTREACH 51 CONCERTA ® 51 Phase IIIb study 51 Joe Lamp'l Master Gardener 51 IN CONFERENCE PLAY 51 tolterodine ER 51 Amanda Farinos dines anonymously 51 mso tstyle colband size 51 Phase Ib II 51 Populus interviewed random 51 Clin J 51 ACR# ACR# 51 Retisert 51 semistructured interviews 51 AEGR 51 Pemetrexed 51 AG DVC# DV camcorder 51 s# s# 51 recurrent metastatic 51 Peginterferon 51 undetectable HBV DNA 51 opinion@dailycardinal.com 51 QIDS SR 51 Comorbidity 51 clopidogrel pretreatment 51 HuMax EGFr 51 pediatric nurse practitioners 51 pedigree Dolph Pulliam 51 ACR# responses 51 Erythropoiesis Stimulating Agents ESAs 51 nurse triage 51 DLQI 51 Prospective Multicenter 51 Tesmilifene 51 bioprosthetic valve 51 CCX# 51 GSK# [001] 51 multicenter placebo controlled 51 = null & 51 surrogate endpoint 51 BCIRG 51 abdominal ultrasounds 51 urinary retention gastric 51 paliperidone ER 51 hepatic lesions 51 multicenter Phase 51 cardiovascular calcification 51 HbA1c levels 51 RE LY trial 51 docetaxel chemotherapy 51 Recurrence Score 51 fosbretabulin 51 Diagnostic Accuracy 51 ELACYT 51 Gene Mutation Linked 51 Helicobacter pylori eradication 51 ULORIC 51 EDEMA4 trial 51 neuropsychological assessments 51 aldosterone antagonists 51 multicentre randomized 51 randomized Phase III 51 ps :# 51 histologically confirmed 51 small molecule Hedgehog 51 cladribine tablets 51 analgesic efficacy 51 Patient Outcomes 51 TEMSO 51 myocardial viability 51 Reduces Mortality 51 retrospective observational study 51 Bronchopulmonary Dysplasia 51 preoperative PSA 51 tipranavir r 51 mg BID 51 adjuvant radiation 51 HBeAg positive patients 51 insulin glulisine 51 Pulsing multicolored diodes 51 HRQL 51 hematological parameters 51 pre operatively 51 label multicenter 51 mg/m2 dose 51 mycophenolate mofetil 51 Ixempra 51 EndoTAGTM 1 51 acute subacute 51 EURIDIS 51 docetaxel Taxotere ® 51 prospective randomized placebo 51 pCR 51 Xelox 51 BR.# 51 randomized multicenter 51 Bowel Project NSABP 51 GOUT 51 non squamous histology 51 Lupuzor ™ 51 clinical trials XIFAXAN 51 Hepatocellular Carcinoma HCC 51 endoscopic remission 51 bendroflumethiazide 51 AVADO 51 extramarital affairs flunk 51 Sorafenib HCC Assessment 51 Follicular Lymphoma 51 polyarticular 51 RadCube 51 pegylated IFN 51 PPO EPO 51 seroprotection 51 CALERIE 51 placebo PBO 51 CANCIDAS 51 refractory cutaneous T 51 cystinosis patients 51 poststroke depression 51 prospective multicenter 51 SYMBICORT pMDI 51 tramiprosate Alzhemed TM 51 BEXXAR therapeutic regimen 51 underwent liver transplantation 51 IL# PE#QQR 51 Nation Spending Habits 51 pharmacokinetic pharmacodynamic 51 Safinamide 51 Trandolapril 51 PTNS 51 Ceplene/IL-2 51 biologic DMARDs 51 vinca alkaloid 51 SVR# 51 operable breast cancer 51 highly adaptable WFO 51 Multicenter Randomized 51 oxycodone IR 51 phase IIb clinical 51 treating neuropathic pain 51 British dadA 51 controlled multicenter Phase 51 tissue perfusion 51 controlled dose escalation 51 microgram kg 51 CaPre TM 51 HBeAg negative 51 theatrical brio 51 Ziprasidone 51 LEAP iLEAP 51 NEVO RES 51 ENESTnd 51 PRADAXA 51 Coremetrics Benchmark 51 VELCADE melphalan 51 Arch Facial Plast 51 Maintain Equal Weight 51 Functional Outcomes 51 II Nutrition Cohort 51 multiple myeloma MM 51 EGRIFTA ™ tesamorelin 51 Arch Intern Med 51 placebo controlled Phase III 51 Therapy Improves 51 Radical prostatectomy 51 T7 refers 51 Taxotere ® 51 stage IIIB 51 Vascugel ® 51 HealthGrades analyzed 51 boys Khoran Brown 51 serum clusterin levels 51 histological subtype 51 very badly Berlinschi 51 ® natalizumab 51 budesonide pMDI 51 CHARISMA trial 51 multicenter randomized Phase III 51 Expanded Disability Status 51 dyslipidaemia 51 HAMD 51 NaviNet Insurer Connect 51 elevated ALT 51 DAILY STOCK ALERTS 51 TORISEL 51 Danazol 51 Post Menopausal 51 pharmacodynamic parameters 51 Clinical Outcomes 51 Adalimumab 51 Q#IR 51 SYNTAX trial 51 DIABETES SELF MANAGEMENT 51 carboplatin paclitaxel 51 Meta analyzes 51 3mg/kg 51 Recap TOR 51 ISEQ Irish 51 Degarelix 51 conditional logistic regression 51 Randomized Study 51 undetectable HCV RNA 51 Severe Asthma 51 antibody MAb 51 Schizophrenia Bulletin 51 = -#.# df 51 serum lipid levels 51 fluoropyrimidine 51 Atypical Hemolytic Uremic Syndrome 51 logistic regression models 51 PK PD modeling 51 ii Immtech ability 51 octreotide LAR 51 Receives URAC Accreditation 51 Cardiorespiratory fitness 50 mg TID 50 PSADT 50 adecatumumab 50 Baseline characteristics 50 Nystatin current 50 ACCOMPLISH 50 posttest 50 dosing cohort 50 Formative assessments 50 histologic subtype 50 subthreshold depression 50 ACR# response 50 celgosivir 50 treat NNT 50 biomarker identification 50 gefitinib Iressa 50 empirically validated 50 TF CBT 50 PLCO 50 mCRC patients 50 Soft Tissue Sarcoma 50 Durezol 50 FDG PET scans 50 somatization disorder 50 rEEG 50 Heart Profilers 50 CVx ChannelVision Expo 50 Gainesville PowerCore Team 50 TABLE #.OS -#/# parent 50 intermittent dosing 50 mcg albinterferon alfa 2b 50 FluCAM arm 50 tarenflurbil 50 Sipuleucel T 50 Comorbidities 50 Taxus Stent 50 Arch Neurol 50 somatization 50 receiving VICTRELIS 50 Fludara 50 neurologists cardiologists 50 shorter telomere length 50 metastatic colorectal 50 HEDIS R 50 topiramate Topamax 50 Clostridium difficile Infection 50 NeuroStar TMS Therapy 50 ABSORB trial 50 sunitinib Sutent 50 ICD therapy 50 Renal Cell Carcinoma RCC 50 sertraline Zoloft 50 SPARLON 50 Heart Failure Therapies 50 atherosclerotic renal artery stenosis 50 RTOG